<DOC>
	<DOCNO>NCT02373579</DOCNO>
	<brief_summary>Study role oxidative stress methotrexate induce hepatic damage , possible protective effect OMEGA-3 fatty acid methotrexate hepatotoxicity use clinical biochemical parameter .</brief_summary>
	<brief_title>Effect Omega-3 Fatty Acids Methotrexate Induced Hepatotoxicity Children With Acute Lymphoblastic Leukemia</brief_title>
	<detailed_description>The patient divide two group : Group I : control group , include pediatric patient standard risk acute lymphoblastic leukemia maintenance phase day 0 receive oral Methotrexate ( 20 mg / m2 ) weekly without supplementation . Group II : study group , include standard risk ALL pediatric patient supplement oral omega-3 capsule ( one capsule / day ) . Omega-3 supplied soft gelatin capsule dose 1000 mg omega-3 fatty acids/day . This addition chemotherapy day one maintenance phase receive oral Methotrexate ( 20 mg / m2 ) Weight -adjusted dos day 8 , 15 , 22 , 29,36,43,50,57,64,71and 78 ) . Both group follow six month . All patient free diet maintain standard diet throughout study ( 6 month ) . None regular vitamin supplementation diagnosis time chemotherapy administration . Patients follow : The patient follow every three week whole study period assess effect compliance MTX Omega-3 fatty acid monitor potential adverse effect . Group I ask visit sign hepatic toxicity ( fatigue , weakness , loss appetite , vague abdominal pain , color urine sclera jaundice ) , laboratory result revise know level ALT marker liver injury . Group II ask visit sign hepatotoxicity , laboratory data revise , side effect result use Omega-3 fatty acid : ( increase bleeding tendency , fishy smell , nausea , diarrhea , relapse occur , sure patient compliant prescribed medication . Investigations : Blood sample collect every patient day 0 maintenance six month estimation Malondialdehyde ( MDA ) , Total antioxidant capacity ( TAC ) , super oxide dismutase , liver function test uric acid . Blood collect heparinised tube protect light process immediately sample . At time collect blood sample , patient free potentially confound interfere condition , infection fever .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<criteria>Child age : le 17 year old . Taking oral methotrexate maintenance therapy . Patients cycle one day zero . Child infect hepatitis B C virus . Child take medication condition cause elevation liver enzymes level methotrexate . ( eg : thrombosis , antibiotic therapy , infiltrate malignancy , auto immune manifestation TPN ) Child remission . Child death Child drop due non compliance</criteria>
	<gender>All</gender>
	<minimum_age>2 Years</minimum_age>
	<maximum_age>16 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>omega-3 fatty acid</keyword>
	<keyword>methotrexate</keyword>
	<keyword>hepatotoxicity</keyword>
</DOC>